Bgm (BGM) Current Deferred Revenue (2019 - 2025)
Bgm's (BGM) quarterly Current Deferred Revenue came in at $80032.0 in Q3 2025, down 83.66% year-on-year from $489784.0 in Q3 2024, and down 97.69% on a QoQ basis from $3.5 million in Q1 2025.
Bgm (BGM) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Current Deferred Revenue data on file, last reported at $80032.0 in Q3 2025.
- On a quarterly basis, Current Deferred Revenue fell 83.66% year-over-year to $80032.0 in Q3 2025; TTM through Sep 2025 was $80032.0, a 83.66% decrease from a year earlier, with the FY2025 full-year figure at $80032.0, down 83.66% from the prior year.
- Current Deferred Revenue for Q3 2025 stood at $80032.0, down from $3.5 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for BGM reached as high as $3227.8 billion in Q1 2022 and fell as low as $76812.0 in Q3 2023.
- Historically, Current Deferred Revenue has averaged $634.6 billion across 5 years, with a median of $489784.0 in 2024.
- Across the five-year window, Current Deferred Revenue plunged 100.0% in 2024 and jumped 784.29% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $351567.0 in 2021, then surged by 58.27% to $556418.0 in 2022, then plunged by 86.2% to $76812.0 in 2023, then surged by 537.64% to $489784.0 in 2024, then slumped by 83.66% to $80032.0 in 2025.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $80032.0 in Q3 2025, $3.5 million in Q1 2025, and $489784.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 80,032.00 |
| Mar 31, 2025 | 3.47 Mn |
| Sep 30, 2024 | 489,784.00 |
| Mar 31, 2024 | 392,518.00 |
| Sep 30, 2023 | 76,812.00 |
| Mar 31, 2023 | 2,484.01 Bn |
| Sep 30, 2022 | 556,418.00 |
| Mar 31, 2022 | 3,227.79 Bn |
| Sep 30, 2021 | 351,567.00 |
| Sep 30, 2020 | 3.51 Mn |
| Sep 30, 2019 | 391,142.00 |